Literature DB >> 4149942

Antiparkinson drugs as causal agents in tardive dyskinesia.

L G Kiloh, J S Smith, S E Williams.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4149942     DOI: 10.5694/j.1326-5377.1973.tb129673.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  7 in total

1.  Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects.

Authors:  A C Sayers; H R Bürki; W Ruch; H Asper
Journal:  Psychopharmacology (Berl)       Date:  1976-12-21       Impact factor: 4.530

2.  Adequate individualized dosages (AID) in perspective.

Authors:  J C Maerz
Journal:  Proc R Soc Med       Date:  1976

3.  Tardive dyskinesia and psychotropic drug history.

Authors:  G M Simpson; E Varga; J H Lee; B Zoubok
Journal:  Psychopharmacology (Berl)       Date:  1978-07-06       Impact factor: 4.530

4.  Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study.

Authors:  C de Montigny; G Chouinard; L Annable
Journal:  Psychopharmacology (Berl)       Date:  1979-11       Impact factor: 4.530

Review 5.  Management of tardive dyskinesia: current update.

Authors:  G M Simpson; E H Pi; J J Sramek
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

6.  Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.

Authors:  U K Rinne; E Birket-Smith; E Dupont; E Hansen; M Hyyppä; R Marttila; B Mikkelsen; H Pakkenberg; J Presthus
Journal:  J Neurol       Date:  1975-12-02       Impact factor: 4.849

7.  Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia.

Authors:  J S Smith; L G Kiloh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-06       Impact factor: 10.154

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.